Aberrant expression of monocarboxylate transporter 4 in tumour cells predicts an unfavourable outcome in patients with hepatocellular carcinoma

Liver International

Volumn 34, Issue 6, 2014, Pages 942-952

  Ohno, Akinobu ^a,b   Yorita, Kenji ^a   Haruyama, Yukihiro ^a   Kondo, Kazuhiro ^a   Kato, Atsuhiko ^c   Ohtomo, Toshihiko ^c   Kawaguchi, Makiko ^a   Marutuska, Kousuke ^b   Chijiiwa, Kazuo ^a   Kataoka, Hiroaki ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b UNIVERSITY OF MIYAZAKI HOSPITAL   (Japan)

^c CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Hepatocellular carcinoma; MCT4; Prognosis; Tumour associated macrophages

Indexed keywords

GLYPICAN 3; MONOCARBOXYLATE TRANSPORTER 4; MONOCARBOXYLATE TRANSPORTER; MUSCLE PROTEIN; SLC16A4 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PROTEIN EXPRESSION; SCORING SYSTEM; TREATMENT OUTCOME; TUMOR CELL; ADOLESCENT; AGED; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; CHI SQUARE DISTRIBUTION; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MONOCARBOXYLIC ACID TRANSPORTERS; MULTIVARIATE ANALYSIS; MUSCLE PROTEINS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84902535310     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12466     Document Type: Article

References (29)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
2. Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 2013; 144: 512-27.
3. Sica A, Larghi P, Mancino A, et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008; 18: 349-55.
4. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013; 23: 277-86.
5. Komohara Y, Hasita H, Ohnishi K, et al. Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci 2011; 102: 1424-31.
6. Shigeoka M, Urakawa N, Nakamura T, et al. Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma. Cancer Sci 2013;104: 1112-9.
7. Ding T, Xu J, Wang F, et al. High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum Pathol 2009; 40: 381-9.
8. Li YW, Qiu SJ, Fan J, et al. Tumor-infiltrating macrophages can predict favorable prognosis in hepatocellular carcinoma after resection. J Cancer Res Clin Oncol 2009; 135: 439-49.
9. Shirabe K, Mano Y, Muto J, et al. Role of tumor-associated macrophages in the progression of hepatocellular carcinoma. Surg Today 2012; 42: 1-7.
10. Pinheiro C, Longatto-Filho A, Azevedo-Silva J, et al. Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr 2012; 44: 127-39.
11. Moreau A, Le Vee M, Jouan E, Parmentier Y, Fardel O. Drug transporter expression in human macrophages. Fundam Clin Pharmacol 2011; 25: 743-52.
12. Ullah MS, Davies AJ, Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem 2006; 281: 9030-7.
13. Yorita K, Takahashi N, Takai H, et al. Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma. Liver Int 2011; 31: 120-31.
14. Takai H, Kato A, Kato C, et al. The expression profile of glypican-3 and its relation to macrophage population in human hepatocellular carcinoma. Liver Int 2009; 29: 1056-64.
15. Ishiguro T, Sugimoto M, Kinoshita Y, et al. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res 2008; 68: 9832-8.
16. Kirk P, Wilson MC, Heddle C, et al. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J 2000; 19: 3896-904.
17. Ho J, de Moura MB, Lin Y, et al. Importance of glycolysis and oxidative phosphorylation in advanced melanoma. Mol Cancer 2012; 11: 76.
18. Curry JM, Tuluc M, Whitaker-Menezes D, et al. Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer. Cell Cycle 2013; 12: 1371-84.
19. Miranda-Goncalves V, Honavar M, Pinheiro C, et al. Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro Oncol 2013; 15: 172-88.
20. Meijer TW, Schuurbiers OC, Kaanders JH, et al. Differences in metabolism between adeno- and squamous cell non-small cell lung carcinomas: spatial distribution and prognostic value of GLUT1 and MCT4. Lung Cancer 2012; 76: 316-23.
21. Gerlinger M, Santos CR, Spencer-Dene B, et al. Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. J Pathol 2012; 227: 146-56.
22. Nakayama Y, Torigoe T, Inoue Y, et al. Prognostic significance of monocarboxylate transporter 4 expression in patients with colorectal cancer. Exp Ther Med 2012; 3: 25-30.
23. Zhang J-B, Guo K, Sun H-C, et al. Prognostic value of peritumoral heat-shock factor-1 in patients receiving resection of hepatocellular carcinoma. Br J Cancer 2013; 109: 1648-56.
24. Hahn JS, Hu Z, Thiele DJ, Iyer VR. Genome-wide analysis of the biology of stress responses through heat shock transcription factor. Mol Cell Biol 2004; 24: 5249-56.
25. Estrella V, Chen T, Lloyd M, et al. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res 2013; 73: 1524-35.
26. Kataoka H, DeCastro R, Zucker S, Biswas C. Tumor cell-derived collagenase-stimulatory factor increases expression of interstitial collagenase, stromelysin, and 72-kDa gelatinase. Cancer Res 1993; 53: 3154-8.
27. Biswas C, Zhang Y, DeCastro R, et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 1995; 55: 434-9.
28. Tang X, Guo N, Xu L, Gou X, Mi M. CD147/EMMPRIN: an effective therapeutic target for hepatocellular carcinoma. J Drug Target 2013; 21: 224-31.
29. Wu J, Ru NY, Zhang Y, et al. HAb18G/CD147 promotes epithelial-mesenchymal transition through TGF-β signaling and is transcriptionally regulated by Slug. Oncogene 2011; 30: 4410-27.